Patients receiving the same intervention can show different biochemical responses. Understanding that variation is not the same as proving a functional benefit. Primary study
What was reported
Thirty-one women, with a mean age of 86, received one of two growth-hormone regimens or placebo for fourteen days after hip-fracture surgery. Both active groups showed IGF-1 and IGFBP-3 responses different from placebo. Individual IGF-1 responses varied with pretreatment frailty indicators. Serious clinical events occurred, without an excess number in the active groups. Primary report
Our appraisal: response heterogeneity is not a treatment-selection rule
A correlation between frailty indicators and a hormone response may help explain variation, but it does not establish who will experience a meaningful clinical benefit. The response marker and the patient-centered outcome need to be connected through appropriate evidence.
Small samples are particularly limited for comparing uncommon adverse outcomes. No observed excess in one study should not be converted into a broad safety assurance. The occurrence of serious events also needs clear attribution rather than assuming that every event was caused by treatment.
Similar biochemical responses across two active regimens do not prove clinical equivalence. That would require a suitable equivalence design and adequate precision on the relevant outcomes.
The short postoperative observation window narrows the conclusions further. It cannot establish durable recovery, long-term independence, or the consequences of prolonged exposure.
The study contributes to understanding endocrine responsiveness in a frail surgical population. It does not provide a validated way to select patients for treatment from a single frailty measure or demonstrate that increasing IGF-1 restores function after hip fracture.
Frequently asked questions
How many women participated?
Thirty-one.
Was the treatment period short?
Yes, fourteen days.
Did active treatment alter IGF-1?
Yes.
Did responses vary between individuals?
Yes.
Does that establish who benefits clinically?
No.
Were serious events entirely absent?
No.
Is long-term safety established?
No.